1209340
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- June 30, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Palm Harbor, FL (United States)
Citations
| ID | CFR | Description |
|---|---|---|
| 1105 | 21 CFR 211.22(d) | Procedures not in writing, fully followed |
| 1169 | 21 CFR 211.42(a) | Buildings of Suitable Size, Construction, Location |
| 1213 | 21 CFR 211.67(a) | Cleaning / Sanitizing / Maintenance |
| 1215 | 21 CFR 211.67(b) | Written procedures not established/followed |
| 1434 | 21 CFR 211.42(c)(10)(iv) | Environmental Monitoring System |
| 1452 | 21 CFR 211.113(b) | Validation lacking for sterile drug products |
| 1868 | 21 CFR 211.94(b) | Protection from external factors |
| 1876 | 21 CFR 211.180(b) | Record maintenance 1 year (except exempt OTC) |
| 2027 | 21 CFR 211.192 | Investigations of discrepancies, failures |
| 2401 | 21 CFR 211.194(a)(4) | Complete Test Data |
| 3567 | 21 CFR 211.84(d)(2) | Component identification test |
| 4345 | 21 CFR 211.160(b)(1) | Samples (various types) representative, identified properly |
| 4357 | 21 CFR 211.166(a) | Results not used for expiration dates, storage cond. |
| 4359 | 21 CFR 211.170(b)(1) | Retention time of reserve samples, in general |
| 4377 | 21 CFR 211.188(b)(3) | Identification of each component or in-process material |